eli lilly glp 1 market share GLP-1 Analogues Size to Hit USD 1,062.90 Billion by 2035 Eli Lilly is not just

Metformin can irritate the digestive tract, while semaglutide slows down digestion significantly

Clinical trials have shown that semaglutide, when prescribed and monitored appropriately, may support significant weight loss

The result is weight regain leading to the recurrence of pre-diabetes, hypertension, dyslipidemia, and other risks , and essentially wasted effort, cost, and time

These medications facilitate weight loss by enhancing feelings of fullness and stabilizing blood sugar levels

Other common gastrointestinal effects include: Vomiting (5-24% of patients) Diarrhea (8-30% of patients) Constipation (10-24% of patients) Abdominal pain or discomfort (5-20% of patients) These side effects are typically most pronounced when initiating therapy or increasing doses, and often diminish over time as the body adjusts to the medication